One In Five Americans Could Develop Skin Cancer In Their Lifetime – AiViva's Novel Drug Approach Could Help

Interested in investing in AiViva’s campaign? Click here to get started!

Cancer is one of the most dreaded diseases in the modern world. In the United States. Skin cancer is the most common form of cancer with current estimates indicating that one in five Americans could potentially develop skin cancer in their lifetime. Research estimates that non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), affects more than 3 million Americans a year.

Basal cell carcinoma (BCC), a non-melanoma skin cancer, is the most common form of skin cancer and also the most frequently occurring of all cancers. BCC is said to occur when changes are triggered in the basal cells in the outermost layer of the skin (called the epidermis) due to DNA damage resulting from exposure to ultraviolet (UV) radiation from the sun, or from indoor tanning. These changes result in the abnormal and uncontrolled growth of basal cells giving rise to BCC.

When detected early, most basal cell carcinomas (BCCs) can be treated and cured but prompt treatment is vital, and certain rare, aggressive forms can be fatal if not treated promptly.

A Promising Potential Treatment For Basal Cell Carcinoma?

One company that is testing a novel approach to treating BCC and believes it could potentially produce transformative outcomes is AiViva Biopharma. 

AiViva says that its treatment is unique because it avoids surgery entirely, and comprises injecting the AiViva compound AIV001 directly into the cancer area. Its proprietary technology enables a prolonged release of AIV001 directly to the targeted cancer without systemic side effects or visible scarring.

AiViva’s clinical trial is ongoing, targeting two of the four main clinical subtypes of basal cell carcinoma: nodular and superficial in patients. The company says that the preliminary data available from this study is promising, and notes that AIV001 is able to demonstrate its ability for histological clearance of BCC skin cancer. This preliminary result affirms AiViva’s belief that AIV001 could potentially treat and cure superficial and nodular basal cell carcinomas.

 “We believe that AIV001 has the potential to transform the treatment paradigm for BCC by offering a disease-modifying therapy providing physicians and patients with an effective treatment.  We look forward to sharing data from our trial at its conclusion.” said Dr. Diane Tang-Liu, President and CEO of AiViva.

The company expects the topline results from the AIV001 trial for BCC to be available in 2023.

About AiViva Biopharma:

AiViva is a clinical stage biotech company founded in 2015 by four pharmaceutical industry veterans with more than 300 years of combined industry experience. AiViva's founders have demonstrated a successful track record across the full spectrum of drug development and commercialization, in addition to raising capital, and IPOs on the NYSE and NASDAQ.

AiViva was formed with the mission of developing novel, innovative pharmaceutical products through an efficient, risk-mitigated development strategy to address major unmet medical needs.

We are developing drug products with the potential to transform treatment paradigms or significantly reduce the treatment burden for patients and physicians. Our approach leverages our proprietary JEL™ Technology to prolong the therapeutic effects of drugs and enhance their benefit-risk profiles. AiViva has a diverse pipeline of multiple novel drug candidates in development areas of dermatology, ophthalmology, oncology, and urology with the potential to expand to other areas of interest.

Click here to invest in AiViva and be a part of their growth story.

If you would like to learn more about the company, check out its website.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. Benzinga may receive monetary compensation from the issuer, or its agency, for publicizing the offering of the issuer’s securities. This content is for informational purposes only and is not intended to be investing advice. This is a paid ad. Please see 17(b) disclosure linked in the campaign page for more information. 

Featured Photo by Anna Tarazevich on Pexels.